{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:54:30Z","timestamp":1784735670623,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06843-2","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:49:12Z","timestamp":1770616152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinico-genomic characterization of RAS-mutant acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Robert","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-5505","authenticated-orcid":false,"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"6843_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al (2013) Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med 368:2059\u20132074","journal-title":"N Engl J Med"},{"key":"6843_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221","journal-title":"N Engl J Med"},{"key":"6843_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35806","volume":"131","author":"J Senapati","year":"2025","unstructured":"Senapati J, Kadia TM, Daver NG, DiNardo CD, Borthakur G, Ravandi F, Kantarjian HM (2025) Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges. Cancer 131:e35806","journal-title":"Cancer"},{"key":"6843_CR4","unstructured":"Cancer Stat Facts Leukemia \u2014 Acute Myeloid Leukemia (AML): National Cancer Institute; https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"6843_CR5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/10428194.2023.2224473","volume":"64","author":"SA Patel","year":"2023","unstructured":"Patel SA (2023) Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7\u2009+\u20093. Leuk Lymphoma 64:1503\u20131513","journal-title":"Leuk Lymphoma"},{"key":"6843_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01054-2","volume":"14","author":"D Alawieh","year":"2024","unstructured":"Alawieh D, Cysique-Foinlan L, Willekens C, Renneville A (2024) RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J 14:72","journal-title":"Blood Cancer J"},{"key":"6843_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144:2169\u20132173","journal-title":"Blood"},{"key":"6843_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cell.2016.03.045","volume":"165","author":"SK Athuluri-Divakar","year":"2016","unstructured":"Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I et al (2016) A small molecule RAS-Mimetic disrupts RAS association with effector proteins to block signaling. Cell 165:643\u2013655","journal-title":"Cell"},{"key":"6843_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F (2017) RAS proteins and their regulators in human disease. Cell 170:17\u201333","journal-title":"Cell"},{"key":"6843_CR10","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457\u20132467","journal-title":"Cancer Res"},{"key":"6843_CR11","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K et al (2024) Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell 42:1614\u20131629e5","journal-title":"Cancer Cell"},{"key":"6843_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ccr.2014.01.029","volume":"25","author":"T Anastassiadis","year":"2014","unstructured":"Anastassiadis T, Brown EJ (2014) Wild-type RAS: keeping mutant RAS in CHK. Cancer Cell 25:137\u2013138","journal-title":"Cancer Cell"},{"key":"6843_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","volume":"8","author":"A Yousef","year":"2024","unstructured":"Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P et al (2024) Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precision Oncol 8:27","journal-title":"NPJ Precision Oncol"},{"key":"6843_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Lievre","year":"2008","unstructured":"Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374\u20139","journal-title":"J Clin Oncol"},{"key":"6843_CR15","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384:2371\u20132381","journal-title":"N Engl J Med"},{"key":"6843_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA Janne","year":"2022","unstructured":"Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM et al (2022) Adagrasib in Non-Small-Cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med 387:120\u2013131","journal-title":"N Engl J Med"},{"key":"6843_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/hon.3099","volume":"41","author":"Y Ren","year":"2023","unstructured":"Ren Y, Lang W, Mei C, Luo Y, Ye L, Wang L et al (2023) Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome. Hematol Oncol 41:159\u2013166","journal-title":"Hematol Oncol"},{"key":"6843_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E et al (2016) Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128:1408\u201317","journal-title":"Blood"},{"key":"6843_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G et al (2024) RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature 636:241\u2013250","journal-title":"Nature"},{"issue":"Suppl1","key":"6843_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2019-125319","volume":"134","author":"BJ Ball","year":"2019","unstructured":"Ball BJ, Hsu M, Devlin SM, Famulare C, Cai SF, Dunbar A et al (2019) RAS mutations are independently associated with decreased overall survival and Event-Free survival in patients with AML receiving induction chemotherapy. Blood 134(Suppl1):18","journal-title":"Blood"},{"key":"6843_CR21","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1182\/blood-2005-08-3522","volume":"107","author":"U Bacher","year":"2006","unstructured":"Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S (2006) Implications of NRAS mutations in AML: a study of 2502 patients. Blood 107:3847\u20133853","journal-title":"Blood"},{"key":"6843_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cca.2018.08.040","volume":"489","author":"X Liu","year":"2019","unstructured":"Liu X, Ye Q, Zhao XP, Zhang PB, Li S, Li RQ et al (2019) RAS mutations in acute myeloid leukaemia patients: a review and meta-analysis. Clin Chim Acta 489:254\u201360","journal-title":"Clin Chim Acta"},{"key":"6843_CR23","first-page":"3074","volume":"93","author":"H Kiyoi","year":"1999","unstructured":"Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074\u20133080","journal-title":"Blood"},{"key":"6843_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/10428194.2023.2190432","volume":"64","author":"MK Mustafa Ali","year":"2023","unstructured":"Mustafa Ali MK, Williams MT, Corley EM, AlKaabba F, Niyongere S (2023) Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia. Leuk Lymphoma 64:962\u2013971","journal-title":"Leuk Lymphoma"},{"key":"6843_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377","journal-title":"Blood"},{"key":"6843_CR26","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1080\/10428194.2021.1957869","volume":"62","author":"SA Patel","year":"2021","unstructured":"Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A et al (2021) Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leuk Lymphoma 62:3348\u20133360","journal-title":"Leuk Lymphoma"},{"key":"6843_CR27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/jha2.791","volume":"4","author":"SA Patel","year":"2023","unstructured":"Patel SA, Cerny J, Gerber WK, Ramanathan M, Ediriwickrema A, Tanenbaum B et al (2023) Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions. EJHaem 4:1059\u20131070","journal-title":"EJHaem"},{"key":"6843_CR28","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/bjh.19423","volume":"204","author":"SA Patel","year":"2024","unstructured":"Patel SA, Gerber WK, Zheng R, Khanna S, Hutchinson L, Abel GA et al (2024) Natural history of clonal haematopoiesis seen in real-world haematology settings. Br J Haematol 204:1844\u20131855","journal-title":"Br J Haematol"},{"key":"6843_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35950","volume":"131","author":"SA Patel","year":"2025","unstructured":"Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B et al (2025) Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer 131:e35950","journal-title":"Cancer"},{"key":"6843_CR30","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB et al (2025) Genetic and phenotypic correlates of clinical outcomes with venetoclax in acute myeloid leukemia: the GEN-PHEN-VEN study. Blood Cancer Discov 6:437\u2013449","DOI":"10.1158\/2643-3230.BCD-24-0256"},{"key":"6843_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00687-5","volume":"12","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F (2022) Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J 12:91","journal-title":"Blood Cancer J"},{"key":"6843_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03393-3","volume":"24","author":"M Sadeghi","year":"2024","unstructured":"Sadeghi M, Moslehi A, Kheiry H, Kiani FK, Zarei A, Khodakarami A et al (2024) The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of heme oxygenase-1 and hypoxia-inducible factor 1-alpha. Cancer Cell Int 24:217","journal-title":"Cancer Cell Int"},{"key":"6843_CR33","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.2007.14.0418","volume":"26","author":"A Neubauer","year":"2008","unstructured":"Neubauer A, Maharry K, Mr\u00f3zek K, Thiede C, Marcucci G, Paschka P et al (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a cancer and leukemia group B study. J Clin Oncol 26:4603\u20134609","journal-title":"J Clin Oncol"},{"key":"6843_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","volume":"39","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG et al (2025) Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39:854\u2013863","journal-title":"Leukemia"},{"key":"6843_CR35","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ajh.27054","volume":"98","author":"TM Kadia","year":"2023","unstructured":"Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N et al (2023) Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98:1711\u20131720","journal-title":"Am J Hematol"},{"key":"6843_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S (2020) Ras-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 19:533\u2013552","journal-title":"Nat Rev Drug Discov"},{"key":"6843_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107293","volume":"184","author":"TKH Lim","year":"2023","unstructured":"Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA et al (2023) KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer 184:107293","journal-title":"Lung Cancer"},{"key":"6843_CR38","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H et al (2022) FDA approval summary: Sotorasib for KRAS G12C-Mutated metastatic NSCLC. Clin Cancer Res 28:1482\u20131486","journal-title":"Clin Cancer Res"},{"key":"6843_CR39","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 28:2171\u20132182","journal-title":"Nat Med"},{"key":"6843_CR40","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/cncr.29986","volume":"122","author":"G Borthakur","year":"2016","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N et al (2016) Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122:1871\u20139","journal-title":"Cancer"},{"key":"6843_CR41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000525566","volume":"145","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ et al (2022) A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations. Acta Haematol 145:529\u2013536","journal-title":"Acta Haematol"},{"key":"6843_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","volume":"19","author":"A Maiti","year":"2019","unstructured":"Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P et al (2019) Phase II trial of MEK inhibitor binimetinib (MEK162) in RAS-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 19:142\u2013148","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6843_CR43","doi-asserted-by":"crossref","unstructured":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I et al (2025) Multiselective RAS(ON) Inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood 147:276\u2013289","DOI":"10.1182\/blood.2025030558"},{"issue":"Supplement 1","key":"6843_CR44","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1182\/blood-2025-4305","volume":"146","author":"C Carlson","year":"2025","unstructured":"Carlson C, Tinajero J, Ngo D, Ma H, Park S, Arslan S (2025) Clearance of RAS pathway mutations prior to allogeneic transplant in acute myeloid leukemia are associated with favorable overall and leukemia free survival. Blood 146(Supplement 1):4305","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06843-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:04:48Z","timestamp":1771949088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6843"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06843-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the UMass Institutional Review Board under general study protocol (IRB#: H00019393) for retrospective analysis of patients with acute myeloid leukemia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}